Display options
Cite
Ivanova AB, Batovska DI, Todorova IT, et al. Comparative Study on the MDR Reversal Effects of Selected Chalcones. Int J Med Chem. 2010;2011:530780doi: 10.1155/2011/530780.
Ivanova, A. B., Batovska, D. I., Todorova, I. T., Stamboliyska, B. A., Serly, J., & Molnar, J. (2011). Comparative Study on the MDR Reversal Effects of Selected Chalcones. International journal of medicinal chemistry, 2011530780. https://doi.org/10.1155/2011/530780
Ivanova, A B, et al. "Comparative Study on the MDR Reversal Effects of Selected Chalcones." International journal of medicinal chemistry vol. 2011 (2011): 530780. doi: https://doi.org/10.1155/2011/530780
Ivanova AB, Batovska DI, Todorova IT, Stamboliyska BA, Serly J, Molnar J. Comparative Study on the MDR Reversal Effects of Selected Chalcones. Int J Med Chem. 2011;2011:530780. doi: 10.1155/2011/530780. Epub 2010 Dec 29. PMID: 27516904; PMCID: PMC4970649.
Copy Download .nbib Format: NLM
Share it on

Int J Med Chem. 2011;2011:530780. doi: 10.1155/2011/530780. Epub 2010 Dec 29.

Comparative Study on the MDR Reversal Effects of Selected Chalcones.

International journal of medicinal chemistry

A B Ivanova, D I Batovska, I T Todorova, B A Stamboliyska, J Serly, J Molnar

Affiliations

  1. Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Street Bl. 9, Sofia 1113, Bulgaria.
  2. Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, 10 Dóm tér, 6720 Szeged, Hungary.

PMID: 27516904 PMCID: PMC4970649 DOI: 10.1155/2011/530780

Abstract

Based on the structure of three previously established lead compounds, fifteen selected chalcones were synthesized and evaluated for their multidrug resistance (MDR) reversal activity on mouse lymphoma cells. The most active chalcones were stronger revertants than the positive control, verapamil. In the model of combination chemotherapy, the interactions between the anticancer drug doxorubicin and two of the most effective compounds were measured in vitro, on human MDR1 gene transfected mouse lymphoma cells, showing that the type of interaction for one of these compounds was indifferent while that for the other one was additive. Furthermore, two chalcones inhibited 50% of cell proliferation in concentration of around 0.4 μg/mL and were from 2- to 100-fold more active than the most chalcones. The structure-activity relationships were obtained and discussed in view of their usefulness for the design of chalcone-like P-gp modulators and drugs able to treat resistant cancers.

References

  1. Chem Biodivers. 2005 Dec;2(12):1656-64 - PubMed
  2. J Pharm Pharm Sci. 2009;12(1):46-78 - PubMed
  3. Eur J Med Chem. 2002 Aug;37(8):699-705 - PubMed
  4. Eur J Pharm Sci. 2008 Sep 2;35(1-2):30-41 - PubMed
  5. Bioorg Med Chem. 2008 Jan 1;16(1):171-80 - PubMed
  6. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46 - PubMed
  7. J Clin Pharm Ther. 2003 Jun;28(3):203-28 - PubMed
  8. Curr Clin Pharmacol. 2010 Feb;5(1):1-29 - PubMed
  9. In Vivo. 2008 May-Jun;22(3):379-84 - PubMed
  10. Bioorg Med Chem. 1999 Dec;7(12):2691-5 - PubMed
  11. Eur J Pharm Sci. 2000 Oct;11(4):265-83 - PubMed
  12. Bioorg Med Chem. 2008 Jan 15;16(2):658-67 - PubMed
  13. Bioorg Med Chem. 2006 Jul 1;14(13):4519-25 - PubMed
  14. Drug Discov Today. 2008 Apr;13(7-8):311-7 - PubMed
  15. Bioorg Med Chem. 2009 Dec 1;17(23):7909-14 - PubMed
  16. Eur J Biochem. 1998 Jan 15;251(1-2):252-61 - PubMed
  17. Curr Med Chem. 2005;12(4):481-99 - PubMed
  18. Planta Med. 1987 Feb;53(1):110-2 - PubMed
  19. J Biol Chem. 1987 Feb 15;262(5):2166-70 - PubMed
  20. Science. 2009 Mar 27;323(5922):1718-22 - PubMed
  21. J Med Chem. 1998 Oct 8;41(21):4161-4 - PubMed
  22. Eur J Med Chem. 2007 Jan;42(1):87-92 - PubMed

Publication Types